BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences PR Newswire LYNBROOK, N.Y., Feb. 27, 2013 LYNBROOK, N.Y., Feb. 27, 2013 /PRNewswire/ --BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX^® in the U.S., announced today that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences. oCowen and Company 33rd Annual Health Care Conference (Boston, MA) Wednesday, March 6, 2013 at 8:40 a.m. EST oROTH Capital Partners 25th Annual Conference (Laguna Niguel, CA) Monday, March 18, 2013 at 5:00 p.m. PDT (8:00 p.m. EDT) The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com. About BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Injectable collagenase is currently marketed as XIAFLEX^® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is approved for Dupuytren's contracture in the European Union, Switzerland and Canada. XIAFLEX is also in clinical development for the treatment of several additional promising indications. A supplemental Biologics License Application is currently under standard review at the U.S. Food and Drug Administration for XIAFLEX for the potential treatment of Peyronie's disease. Auxilium is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials. Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of injectable collagenase for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico. Pfizer Inc. has marketing rights to XIAPEX^® (the EU trade name for XIAFLEX) for Dupuytren's contracture in 46 countries in Eurasia through April 24, 2013. For more information, please visit www.biospecifics.com. SOURCE BioSpecifics Technologies Corp. Website: http://www.biospecifics.com Contact: BioSpecifics Technologies Corp., Thomas L. Wegman, President, +1-516-593-7000, firstname.lastname@example.org
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
Press spacebar to pause and continue. Press esc to stop.